8-K: Propanc Biopharma Secures High-Interest Convertible Note Amidst Financial Strain

Propanc Biopharma, Inc. has entered into a convertible promissory note agreement for $112,350 at a 10% interest rate with punitive default and conversion terms, signaling potential financial distress and significant future dilution.

Summary

• Propanc Biopharma, Inc. (the 'Company') entered into a Securities Purchase Agreement with 1800 Diagonal Lending LLC (the 'Holder') on July 22, 2025, effective July 25, 2025.
• The Company issued a convertible promissory note (the 'Note') with a principal amount of $112,350 to the Holder for a purchase price of $107,000, reflecting an Original Issue Discount (OID) of $5,350.
• The Note bears interest at a rate of 10% per annum, with a default interest rate of 22% per annum.
• The Maturity Date for the Note is April 30, 2026.
• The Holder has the right to convert the Note into Common Stock starting 180 days after the Issue Date, at a variable conversion price equal to 75% of the average lowest trading price of the Common Stock during the ten trading days prior to conversion.
• Conversions are subject to a 4.99% beneficial ownership limitation for the Holder and its affiliates, which cannot be waived.
• The Company is required to reserve five times the number of shares issuable upon full conversion of the Note.
• The Company has limited prepayment rights: 120% of the outstanding amount if prepaid within 90 days of the Issue Date, and 125% if prepaid between 91 and 180 days. After 180 days, the Company loses its prepayment right.
• The Company will use the net proceeds from the Note for general working capital purposes.
• The Company is obligated to reimburse the Holder $7,000 for legal fees and due diligence expenses.

Sentiment

Score: 2

Explanation: The terms of this convertible note are extremely unfavorable to the Company and its shareholders, indicating severe financial distress and a high likelihood of significant future dilution. The high cost of capital, aggressive conversion terms, and punitive default provisions suggest a desperate need for funding with limited alternatives.

Positives

• Secured $107,000 in immediate working capital to support general operations.

Negatives

• The Note carries a high annual interest rate of 10%, escalating to 22% upon default, indicating a high cost of capital.
• The purchase price of $107,000 for a $112,350 principal amount includes a $5,350 Original Issue Discount, effectively increasing the cost of borrowing.
• The variable conversion price, set at a 25% discount to the lowest 10-day average trading price, is highly dilutive to existing shareholders, often referred to as 'death spiral' financing.
• Punitive prepayment penalties of 120% to 125% of the outstanding amount apply if the Company prepays within the first 180 days, and the Company loses its prepayment right entirely after 180 days, which coincides with the Holder's conversion right activation.
• Severe default provisions include immediate acceleration of the Note, requiring payment of 150% of the outstanding amount (or 200% for failure to issue shares), or forced conversion into common stock at the dilutive conversion price.

Risks

• Significant shareholder dilution due to the variable conversion price at a 25% discount to market price.
• Increased financial burden from high interest rates and punitive default interest.
• Risk of immediate acceleration of debt and substantial penalties (150% to 200% of outstanding amount) upon various events of default.
• Potential for further dilution if the Company fails to pay default amounts, leading to forced conversion into common stock.
• Risk of delisting if the Common Stock fails to maintain its listing on specified OTC markets or equivalent exchanges.
• Risk of non-compliance with SEC reporting requirements, which constitutes an event of default.
• Operational disruption or cessation if the Company cannot meet its financial obligations or maintain its transfer agent relationships.
• Cross-default provisions mean a default under any other agreement with the Holder could trigger a default on this Note.

Future Outlook

The Company intends to use the net proceeds from the convertible note for general working capital purposes. No specific forward-looking guidance on operations or financial performance is provided beyond this general statement.

Industry Context

This type of highly dilutive and expensive convertible debt financing, often termed 'toxic' or 'death spiral' financing, is typically utilized by small-cap companies, particularly in the biotech sector, that are experiencing significant financial distress or have limited access to traditional capital markets. The terms, including a high interest rate, original issue discount, variable conversion price at a substantial discount, and punitive default clauses, are indicative of a company in a weak bargaining position, unable to secure more favorable funding. Such agreements often lead to substantial dilution for existing shareholders as the investor converts debt into equity at depressed prices, further pressuring the stock.

Comparison to Industry Standards

• The 10% annual interest rate and 22% default interest rate are significantly higher than typical corporate debt for financially stable companies, which usually range from 3-8%, reflecting the high risk perceived by the lender.
• The 25% discount on the variable conversion price (75% of the lowest 10-day average trading price) is an aggressive term, far exceeding standard convertible note structures which often feature fixed conversion prices or smaller discounts, and is designed to maximize investor profit through dilution.
• The punitive prepayment penalties (120-125%) and the loss of prepayment rights after 180 days are highly unfavorable to the Company, contrasting sharply with more flexible prepayment options in conventional financing.
• The severe default penalties, including 150% to 200% of the outstanding amount becoming immediately due, are indicative of a lender taking an extremely strong position against a distressed borrower, unlike typical debt covenants that might allow for more structured remedies.
• This financing structure is comparable to other highly distressed micro-cap biotech companies that resort to last-resort funding mechanisms when traditional equity or debt markets are inaccessible due to poor financial health or lack of significant progress in their pipeline.

Stakeholder Impact

• Shareholders: Face significant risk of dilution due to the variable conversion price and potential for forced conversion upon default. The stock price is likely to be negatively impacted.
• Creditors: The Holder (1800 Diagonal Lending LLC) is in a strong position with high interest rates, punitive default terms, and a mechanism for converting debt to equity at a discount, prioritizing their recovery.
• Employees: While the capital provides immediate working capital, the underlying financial distress and dilutive financing terms could create uncertainty regarding the Company's long-term stability.

Next Steps

• The Company will need to manage its cash flow to service the interest payments on the Note.
• The Company will need to prepare for potential conversion of the Note into common stock by the Holder, which could lead to significant share dilution.
• The Company must ensure compliance with all covenants, including maintaining its listing on the OTC markets and fulfilling SEC reporting requirements, to avoid triggering events of default.

Key Dates

Recommendation

The terms of this convertible note are highly detrimental to existing shareholders, signaling severe financial distress and a high probability of substantial future dilution. The high interest rate, significant discount on conversion, and punitive default clauses indicate the company is in a precarious financial position. This type of financing typically leads to sustained downward pressure on the stock price as the investor converts debt into shares, flooding the market. Investors should consider exiting their positions to avoid further value erosion.

Keywords

Propanc Biopharma, Convertible Note, Promissory Note, Debt Financing, Dilution, SEC Filing, 8-K, Financial Distress, Working Capital, OTC Markets, Variable Conversion Price, Original Issue Discount